NVOH - ETF AI Analysis
Top Page
Novo Nordisk A/S (B Shares) ADRhedged (NVOH)
Rating:71Outperform
Price Target:―
Positive Factors
Recent Short-Term Rebound
The ETF has shown strong gains over the past one and three months, suggesting improving short-term momentum despite a weaker year-to-date result.
Focused Exposure to a Leading Healthcare Name
The fund is heavily invested in Novo Nordisk, a major healthcare company, giving investors targeted exposure to a well-known player in the sector.
Low Expense Ratio
The ETF charges a relatively low fee, which helps investors keep more of their returns over time.
Negative Factors
High Single-Stock Concentration
With nearly all assets in one company, investors face elevated risk if that single stock performs poorly.
Year-to-Date Underperformance
The ETF’s overall performance so far this year has been weak, reflecting recent softness in its main holding.
Limited Sector and Geographic Diversification
The fund is concentrated in U.S.-listed healthcare exposure, offering little protection if that sector or region experiences a downturn.
NVOH vs. SPDR S&P 500 ETF (SPY)
AUM4.46M
RegionEurope
Expense Ratio0.19%
Beta1.05
IssuerADRhedged
Inception DateJan 07, 2025
Dividend Yield6.68%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,532
30 Day Avg. Volume2,021
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
24.25Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NVOH Summary
NVOH is an ETF that focuses on Novo Nordisk, a major global healthcare and pharmaceutical company known for its diabetes and obesity treatments. It doesn’t track a broad index, but instead gives targeted exposure to this single company, while using a currency hedge to reduce the impact of foreign exchange swings for U.S. investors. Someone might invest in NVOH if they believe Novo Nordisk will continue to grow as demand for specialized healthcare and chronic disease treatments increases. A key risk is that the ETF is heavily concentrated in one company, so its value can rise or fall sharply with Novo Nordisk’s fortunes.
How much will it cost me?The NVOH ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed funds, as it focuses on a specific company and niche within the healthcare sector, keeping costs relatively modest.
What would affect this ETF?The NVOH ETF could benefit from the growing global demand for innovative healthcare solutions, particularly in diabetes and obesity treatments, areas where Novo Nordisk is a leader. However, potential risks include regulatory changes in the pharmaceutical industry or shifts in healthcare policies that could impact drug pricing and market access. Additionally, while the fund mitigates currency risk, broader economic challenges in Europe or Denmark could still influence its performance.
NVOH Top 10 Holdings
NVOH is essentially a one-stock story, with Novo Nordisk doing almost all the heavy lifting. The Danish pharma giant has been rising over the past few months on the back of strong demand for its diabetes and obesity treatments, even though its year-to-date performance has been a bit mixed and occasionally loses steam on technical worries and market-share concerns. With nearly all the fund in this single European health care name, investors are making a focused bet on Novo Nordisk rather than a broad basket of global pharmaceuticals.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novo Nordisk | 97.79% | $3.97M | $209.53B | -2.30% | 73 Outperform |
NVOH Technical Analysis
Neutral
―
Price Trends
25.37
Positive
23.38
Positive
24.67
Positive
Market Momentum
0.40
Positive
41.81
Neutral
63.42
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NVOH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 26.95, equal to the 50-day MA of 25.37, and equal to the 200-day MA of 24.67, indicating a neutral trend. The MACD of 0.40 indicates Positive momentum. The RSI at 41.81 is Neutral, neither overbought nor oversold. The STOCH value of 63.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NVOH.
NVOH Peer Comparison
Comparison Results
Performance Comparison
NVOH
Novo Nordisk A/S (B Shares) ADRhedged
25.41
0.35
1.40%
ASMH
ASML Holding NV ADRhedged
―
―
―
ARMH
Arm Holdings PLC ADRhedged
―
―
―
HSBH
HSBC Holdings plc ADRhedged
―
―
―
STHH
STMicroelectronics NV ADRhedged
―
―
―
GSKH
GSK plc ADRhedged
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents